April 8, 2026 —
Life Biosciences, a Boston-based biotechnology company co-founded by Harvard biologist David Sinclair, has raised $80 million in Series D financing to advance a novel AAV-based gene therapy platform designed to rejuvenate aging cells. The funding will support a Phase 1 clinical trial in vision loss as well as additional preclinical studies exploring cellular rejuvenation in other tissues.
The company’s approach is based on the concept of partial epigenetic reprogramming, a strategy aimed at restoring youthful cellular function by resetting portions of the epigenetic code—the chemical markers that regulate how genes are expressed without altering the underlying DNA sequence. According to researchers, age-related decline may occur in part because cells lose epigenetic information over time, leading to impaired function.
Life Biosciences’ therapy uses adeno-associated virus (AAV2) vectors to deliver genetic instructions for three Yamanaka factors—OCT4, SOX2, and KLF4—proteins known to reprogram cells toward a more youthful state. Unlike full cellular reprogramming, which can revert cells into pluripotent stem cells and carry significant cancer risk, the company’s strategy aims to partially reset epigenetic markers without erasing cellular identity.
To improve safety, the therapy incorporates a second AAV2 vector encoding a molecular “safety switch.” This switch allows physicians to control gene expression through an oral medication: when patients take the pill, the therapy activates; when the pill is discontinued, expression of the reprogramming factors stops. Preclinical animal studies have demonstrated that this system can turn the therapy on and off repeatedly over extended periods, providing an additional safety layer.
The Phase 1 clinical trial represents one of the first major clinical tests of partial epigenetic reprogramming in humans. The study will evaluate safety and explore early signs of biological activity in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION)—two conditions involving damage to retinal ganglion cells, which form the optic nerve connecting the eye to the brain.
Retinal ganglion cells are particularly attractive targets for regenerative therapies because they are critical for transmitting visual signals yet have limited ability to regenerate once damaged. The goal of the therapy is to restore function to injured cells by reversing aspects of the aging process, potentially improving vision or slowing degeneration.
The concept builds on earlier academic work from Sinclair’s laboratory, which demonstrated in animal models that AAV-mediated delivery of three Yamanaka factors could restore youthful epigenetic patterns and reverse vision loss in mice with glaucoma. These findings helped establish the scientific basis for the company’s clinical program.
The initial clinical study is small and primarily designed to assess safety, with two dose levels tested in cohorts of three to six patients each. While researchers will measure multiple ophthalmic endpoints, including structural and functional indicators of retinal health, investigators emphasize that safety will be the primary outcome at this stage.
Beyond ophthalmology, Life Biosciences plans to explore the broader potential of partial epigenetic reprogramming for age-related diseases affecting other organs. Preclinical studies have already examined applications in fatty liver disease, and the company expects to disclose additional research directions in the coming years.
With the new financing, Life Biosciences’ total funding now approaches $240 million, providing resources to support clinical development and expand research into gene therapy approaches aimed at cellular rejuvenation and aging biology.
